RCLARITY:利妥昔单抗联合来那度胺和西达本胺治疗复发/难治性血管免疫母细胞性T细胞淋巴瘤的前瞻性II期研究
RCLARITY是一项单臂、多中心、前瞻性II期试验,评估无化疗方案RLC(利妥昔单抗+来那度胺+西达本胺)在复发/难治性AITL患者中的疗效与安全性。共纳入28例患者,ORR为71.4%(CR 32.1%),中位PFS 5.5个月,中位OS 17.6个月,毒性可控,无5级不良事件或静脉血栓栓塞事件。
要点
- RLC方案在r/r AITL中ORR达71.4%,CR率32.1%,中位PFS 5.5个月。
- 中位OS 17.6个月,缓解者中位DoR 10.7个月。
- 基线EBV-DNA阳性患者均在2周期后转阴,无5级不良事件或VTE。
核心结论
- RLC方案在复发/难治性AITL中诱导具有临床意义的抗肿瘤活性,且毒性可控。
研究设计与样本
- 单臂、多中心、前瞻性II期试验(RCLARITY),2019年8月至2024年6月纳入28例成人r/r AITL患者。
- 患者接受利妥昔单抗375 mg/m2静脉第1天、来那度胺15 mg口服第1-21天、西达本胺30 mg口服每周两次,28天为一周期,最多6周期。
- 主要终点为无进展生存期(PFS),次要终点包括总缓解率(ORR)、总生存期(OS)、缓解持续时间(DoR)和安全性。
主要发现
- 中位年龄64岁(范围44-70),71.4%为难治性疾病。
- ORR为71.4%(完全缓解32.1%),中位PFS 5.5个月(95%CI 3.5-7.6),中位OS 17.6个月(95%CI 10.3-24.8)。
- 缓解者中位DoR为10.7个月(95%CI 2.7-16.0)。
- 50%的克隆性Ig重链或轻链重排患者PFS>16个月。
- 基线血清EBV-DNA阳性的9例患者均在2周期后转为不可测。
临床怎么用
- 对于复发/难治性AITL,RLC全口服无化疗方案可作为候选治疗选择,尤其适用于不能耐受传统化疗者。
- 治疗期间需监测血液学毒性,但无需常规担忧VTE风险。
- 基线EBV-DNA阳性患者可预期2周期后转阴。
局限性
- 单臂设计,无随机对照,样本量较小(28例)。
- 随访时间及长期生存数据需进一步观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapsed/refractory (r/r) angioimmunoblastic T-cell lymphoma (AITL) is associated with a dismal prognosis, with historical overall survival (OS) < 6 months, underscoring the urgent need for novel therapies. We conducted the RCLARITY trial to evaluate the efficacy and safety of a chemotherapy-free regimen in this patient population. This single-arm, multicenter, prospective Phase II trial enrolled adult patients with r/r AITL. Patients received rituximab (375 mg/m2 intravenously on Day 1), lenalidomide (15 mg orally on Days 1-21), and chidamide (30 mg orally twice weekly) in 28-day cycles for up to 6 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints included the overall response rate (ORR), OS, duration of response (DoR), and safety. In total, 28 patients were enrolled between August 2019 and June 2024. The median age was 64 years (range, 44-70), and 71.4% had refractory disease. The ORR was 71.4% (complete remission: 32.1%), median PFS was 5.5 months (95% confidence interval [CI], 3.5-7.6), median OS was 17.6 months (95% CI, 10.3-24.8), and median DoR among responders was 10.7 months (95% CI, 2.7-16.0). Notably, 50% of patients with clonal Ig heavy- or light-chain rearrangements achieved PFS > 16 months. All nine patients with baseline serum EBV-DNA positivity converted to undetectable levels after two cycles. No Grade 5 adverse events or venous thromboembolic events occurred. The most common hematological adverse events per cycle were leukopenia (14.3%), thrombocytopenia (12.4%), and neutropenia (11.4%). Overall, the RLC regimen induced clinically meaningful anti-tumor activity with manageable toxicity in patients with r/r AITL. Trial Registration: ClinicalTrials.gov identifier: NCT04319601.
引用
- Li C, Lei T, Xu X, et al. RCLARITY: A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide (RLC) for the Treatment of Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma. Am J Hematol. 2026. PMID: 42124356. doi:10.1002/ajh.70366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。